Literature DB >> 29222398

Cerebral Palsy in Extremely Preterm Infants.

Maria Hafström1,2,3, Karin Källén4, Fredrik Serenius5,6, Karel Maršál4, Eva Rehn7, Helen Drake7, Ulrika Ådén8, Aijaz Farooqi6, Kristina Thorngren-Jerneck9, Bo Strömberg5.   

Abstract

BACKGROUND AND OBJECTIVES: The risk of cerebral palsy (CP) is high in preterm infants and is often accompanied by additional neurodevelopmental comorbidities. The present study describes lifetime prevalence of CP in a population-based prospective cohort of children born extremely preterm, including the type and severity of CP and other comorbidities (ie, developmental delay and/or cognitive impairment, neurobehavioral morbidity, epilepsy, vision and hearing impairments), and overall severity of disability. In this study, we also evaluate whether age at assessment, overall severity of disability, and available sources of information influence outcome results.
METHODS: All Swedish children born before 27 weeks' gestation from 2004 to 2007 were included (the Extremely Preterm Infants in Sweden Study). The combination of neonatal information, information from clinical examinations and neuropsychological assessments at 2.5 and 6.5 years of age, original medical chart reviews, and extended chart reviews was used.
RESULTS: The outcome was identified in 467 (94.5%) of eligible children alive at 1 year of age. Forty-nine (10.5%) children had a lifetime diagnosis of CP, and 37 (76%) were ambulatory. Fourteen (29%) had CP diagnosed after 2.5 years of age, 37 (76%) had at least 1 additional comorbidity, and 27 (55%) had severe disability. The probability for an incomplete evaluation was higher in children with CP compared with children without CP.
CONCLUSIONS: Children born extremely preterm with CP have various comorbidities and often overall severe disability. The importance of long-term follow-up and of obtaining comprehensive outcome information from several sources in children with disabilities is shown.
Copyright © 2018 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2017        PMID: 29222398     DOI: 10.1542/peds.2017-1433

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  18 in total

1.  Development and Validation of a Deep Learning Method to Predict Cerebral Palsy From Spontaneous Movements in Infants at High Risk.

Authors:  Daniel Groos; Lars Adde; Sindre Aubert; Lynn Boswell; Raye-Ann de Regnier; Toril Fjørtoft; Deborah Gaebler-Spira; Andreas Haukeland; Marianne Loennecken; Michael Msall; Unn Inger Möinichen; Aurelie Pascal; Colleen Peyton; Heri Ramampiaro; Michael D Schreiber; Inger Elisabeth Silberg; Nils Thomas Songstad; Niranjan Thomas; Christine Van den Broeck; Gunn Kristin Øberg; Espen A F Ihlen; Ragnhild Støen
Journal:  JAMA Netw Open       Date:  2022-07-01

2.  Neurodevelopmental outcome of Italian preterm ELBW infants: an eleven years single center cohort.

Authors:  Camilla Caporali; Stefania Longo; Giovanna Tritto; Gianfranco Perotti; Camilla Pisoni; Cecilia Naboni; Barbara Gardella; Arsenio Spinillo; Federica Manzoni; Stefano Ghirardello; Renato Borgatti; Simona Orcesi
Journal:  Ital J Pediatr       Date:  2022-07-19       Impact factor: 3.288

Review 3.  Public Health Implications of Very Preterm Birth.

Authors:  Wanda D Barfield
Journal:  Clin Perinatol       Date:  2018-09       Impact factor: 3.430

4.  Hand Function at 18-22 Months Is Associated with School-Age Manual Dexterity and Motor Performance in Children Born Extremely Preterm.

Authors:  Andrea F Duncan; Carla M Bann; Nathalie L Maitre; Myriam Peralta-Carcelen; Susan R Hintz
Journal:  J Pediatr       Date:  2020-05-28       Impact factor: 4.406

5.  Early prediction of neurodevelopmental outcomes at 12 years in children born extremely preterm.

Authors:  Maria Örtqvist; Christa Einspieler; Ulrika Ådén
Journal:  Pediatr Res       Date:  2021-05-10       Impact factor: 3.953

6.  Effects of Phosphatidylserine Source of Docosahexaenoic Acid on Cerebellar Development in Preterm Pigs.

Authors:  Daniel Chizhikov; Randal K Buddington; Igor Y Iskusnykh
Journal:  Brain Sci       Date:  2020-07-23

7.  Trends in Prevalence and Severity of Pre/Perinatal Cerebral Palsy Among Children Born Preterm From 2004 to 2010: A SCPE Collaboration Study.

Authors:  Catherine Arnaud; Virginie Ehlinger; Malika Delobel-Ayoub; Dana Klapouszczak; Oliver Perra; Owen Hensey; David Neubauer; Katalin Hollódy; Daniel Virella; Gija Rackauskaite; Andra Greitane; Kate Himmelmann; Els Ortibus; Ivana Dakovic; Guro L Andersen; Antigone Papavasiliou; Elodie Sellier; Mary Jane Platt; Inge Krägeloh-Mann
Journal:  Front Neurol       Date:  2021-05-20       Impact factor: 4.003

8.  Mechanically assisted walking training for walking, participation, and quality of life in children with cerebral palsy.

Authors:  Hsiu-Ching Chiu; Louise Ada; Theofani A Bania
Journal:  Cochrane Database Syst Rev       Date:  2020-11-18

9.  The Predictive Accuracy of the General Movement Assessment for Cerebral Palsy: A Prospective, Observational Study of High-Risk Infants in a Clinical Follow-Up Setting.

Authors:  Ragnhild Støen; Lynn Boswell; Raye-Ann de Regnier; Toril Fjørtoft; Deborah Gaebler-Spira; Espen Ihlen; Cathrine Labori; Marianne Loennecken; Michael Msall; Unn Inger Möinichen; Colleen Peyton; Annamarie Russow; Michael D Schreiber; Inger Elisabeth Silberg; Nils Thomas Songstad; Randi Vågen; Gunn Kristin Øberg; Lars Adde
Journal:  J Clin Med       Date:  2019-10-25       Impact factor: 4.241

10.  Cerebral near-infrared spectroscopy monitoring versus treatment as usual for extremely preterm infants: a protocol for the SafeBoosC randomised clinical phase III trial.

Authors:  Mathias Lühr Hansen; Adelina Pellicer; Christian Gluud; Eugene Dempsey; Jonathan Mintzer; Simon Hyttel-Sørensen; Anne Marie Heuchan; Cornelia Hagmann; Ebru Ergenekon; Gabriel Dimitriou; Gerhard Pichler; Gunnar Naulaers; Guoqiang Cheng; Hercilia Guimarães; Jakub Tkaczyk; Karen B Kreutzer; Monica Fumagalli; Olivier Claris; Petra Lemmers; Siv Fredly; Tomasz Szczapa; Topun Austin; Janus Christian Jakobsen; Gorm Greisen
Journal:  Trials       Date:  2019-12-30       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.